Skip to content
Screener

Agios Pharmaceuticals AGIO Q3 2025 earnings

Reported October 30, 2025 · Before market open

Revenue$12.9MBeat by $1.2M
EPS-$1.78Beat by $0.15
Revenue estimate$11.7M
EPS estimate-$1.93

Next report

Oct 29, 2026 (in a month)
Revenue estimate$53.8M
EPS estimate-$1.21

Financials

Q3 2025

Income statement

See full
Revenue$12.9M+43.7%
Gross profit$11.2M+36.9%
Operating income-$116.9M-13.7%
Net income-$103.4M-111%
EPS (diluted)-$1.78-111%

Balance sheet

See full
Cash & equivalents$92.7M-63.5%
Total debt$44.5M-26.8%
Total equity$1.3B-21.0%
Total assets$1.4B-22.7%

Cash flow

See full
Operating cash flow-$88.2M-4.7%
CapEx$1.6M+271%
Free cash flow-$89.7M-6.0%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$2.33B-7.7%
Enterprise value$2.28B-2.2%
P/S52.1×-24.8×

Profitability

See full
Gross margin87.2%-2.2pp
Operating margin-1,061.8%-132pp
FCF margin-924.5%-68.0pp

Returns & leverage

See full
Debt / equity0×0.0×
Current ratio13.8×+4.8×

FAQ

When did Agios Pharmaceuticals report Q3 2025 earnings?
Agios Pharmaceuticals (AGIO) reported Q3 2025 earnings on October 30, 2025 before market open.
What were Agios Pharmaceuticals's Q3 2025 revenue and EPS?
Agios Pharmaceuticals reported revenue of $12.9M and eps of $-1.78 for Q3 2025.
Did Agios Pharmaceuticals beat estimates in Q3 2025?
Revenue beat the consensus estimate of $11.7M by $1.2M. EPS beat the consensus estimate of $-1.93 by $0.15.
How did Agios Pharmaceuticals's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 43.7% from $9.0M a year earlier.
Where can I find Agios Pharmaceuticals's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001439222-25-000114) and the 10-Q periodic report (0001439222-25-000116) directly on SEC EDGAR. The filing index links above go to sec.gov.